---
document_datetime: 2025-12-29 13:01:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-krka-dd.html
document_name: lenalidomide-krka-dd.html
version: success
processing_time: 0.152183
conversion_datetime: 2025-12-30 09:16:05.732031
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lenalidomide Krka d.d.

[RSS](/en/individual-human-medicine.xml/67404)

##### Withdrawn

This medicine's authorisation has been withdrawn

lenalidomide Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lenalidomide Krka d.d.](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 8 June 2023, the European Commission withdrew the marketing authorisation for Lenalidomide Krka d.d. (lenalidomide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, KRKA, d.d., Novo mesto, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Lenalidomide Krka d.d. was granted marketing authorisation in the EU on 11 February 2021 for the treatment of multiple myeloma, myelodysplastic syndromes and follicular lymphoma. The marketing authorisation was initially valid for a 5-year period.

Lenalidomide Krka d.d. is a generic medicine of Revlimid. There are other generic medicinal products of Revlimid authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Lenalidomide Krka d.d. is updated to indicate that the marketing authorisation is no longer valid.

Lenalidomide Krka d.d. : EPAR - Medicine overview

Reference Number: EMA/11795/2021

English (EN) (259.95 KB - PDF)

**First published:** 18/02/2021

**Last updated:** 10/07/2023

[View](/en/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-352)

български (BG) (328.92 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/bg/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_bg.pdf)

español (ES) (261.29 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/es/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_es.pdf)

čeština (CS) (306.79 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/cs/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_cs.pdf)

dansk (DA) (259.24 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/da/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_da.pdf)

Deutsch (DE) (272.07 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/de/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_de.pdf)

eesti keel (ET) (239.19 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/et/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_et.pdf)

ελληνικά (EL) (332.87 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/el/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_el.pdf)

français (FR) (262.92 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/fr/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_fr.pdf)

hrvatski (HR) (289.32 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/hr/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_hr.pdf)

italiano (IT) (259.7 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/it/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (316.38 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/lv/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (298.84 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/lt/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_lt.pdf)

magyar (HU) (231.4 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/hu/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_hu.pdf)

Malti (MT) (312.79 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/mt/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_mt.pdf)

Nederlands (NL) (265.95 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/nl/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_nl.pdf)

polski (PL) (304.28 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/pl/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_pl.pdf)

português (PT) (260.47 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/pt/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_pt.pdf)

română (RO) (305.2 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/ro/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_ro.pdf)

slovenčina (SK) (300.72 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sk/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_sk.pdf)

slovenščina (SL) (226.58 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sl/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_sl.pdf)

Suomi (FI) (191.78 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/fi/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_fi.pdf)

svenska (SV) (256.36 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sv/documents/overview/lenalidomide-krka-dd-epar-medicine-overview_sv.pdf)

Lenalidomide Krka d.d. : EPAR - Risk-management-plan summary

English (EN) (470.17 KB - PDF)

**First published:** 18/02/2021

**Last updated:** 10/07/2023

[View](/en/documents/rmp-summary/lenalidomide-krka-dd-epar-risk-management-plan-summary_en.pdf)

## Product information

Lenalidomide Krka d.d. : EPAR - Product information

English (EN) (2.78 MB - PDF)

**First published:** 18/02/2021

**Last updated:** 10/07/2023

[View](/en/documents/product-information/lenalidomide-krka-dd-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-752)

български (BG) (3.09 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/bg/documents/product-information/lenalidomide-krka-dd-epar-product-information_bg.pdf)

español (ES) (2.4 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/es/documents/product-information/lenalidomide-krka-dd-epar-product-information_es.pdf)

čeština (CS) (2.6 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/cs/documents/product-information/lenalidomide-krka-dd-epar-product-information_cs.pdf)

dansk (DA) (2.33 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/da/documents/product-information/lenalidomide-krka-dd-epar-product-information_da.pdf)

Deutsch (DE) (2.42 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/de/documents/product-information/lenalidomide-krka-dd-epar-product-information_de.pdf)

eesti keel (ET) (2.23 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/et/documents/product-information/lenalidomide-krka-dd-epar-product-information_et.pdf)

ελληνικά (EL) (2.68 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/el/documents/product-information/lenalidomide-krka-dd-epar-product-information_el.pdf)

français (FR) (2.45 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/fr/documents/product-information/lenalidomide-krka-dd-epar-product-information_fr.pdf)

hrvatski (HR) (2.43 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/hr/documents/product-information/lenalidomide-krka-dd-epar-product-information_hr.pdf)

íslenska (IS) (2.37 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/is/documents/product-information/lenalidomide-krka-dd-epar-product-information_is.pdf)

italiano (IT) (2.27 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/it/documents/product-information/lenalidomide-krka-dd-epar-product-information_it.pdf)

latviešu valoda (LV) (2.36 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/lv/documents/product-information/lenalidomide-krka-dd-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.42 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/lt/documents/product-information/lenalidomide-krka-dd-epar-product-information_lt.pdf)

magyar (HU) (2.8 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/hu/documents/product-information/lenalidomide-krka-dd-epar-product-information_hu.pdf)

Malti (MT) (2.9 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/mt/documents/product-information/lenalidomide-krka-dd-epar-product-information_mt.pdf)

Nederlands (NL) (2.36 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/nl/documents/product-information/lenalidomide-krka-dd-epar-product-information_nl.pdf)

norsk (NO) (2.39 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/no/documents/product-information/lenalidomide-krka-dd-epar-product-information_no.pdf)

polski (PL) (2.49 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/pl/documents/product-information/lenalidomide-krka-dd-epar-product-information_pl.pdf)

português (PT) (2.41 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/pt/documents/product-information/lenalidomide-krka-dd-epar-product-information_pt.pdf)

română (RO) (2.72 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/ro/documents/product-information/lenalidomide-krka-dd-epar-product-information_ro.pdf)

slovenčina (SK) (2.11 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sk/documents/product-information/lenalidomide-krka-dd-epar-product-information_sk.pdf)

slovenščina (SL) (2.35 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sl/documents/product-information/lenalidomide-krka-dd-epar-product-information_sl.pdf)

Suomi (FI) (2.38 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/fi/documents/product-information/lenalidomide-krka-dd-epar-product-information_fi.pdf)

svenska (SV) (2.15 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sv/documents/product-information/lenalidomide-krka-dd-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0003 13/12/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lenalidomide Krka d.d. : EPAR - All authorised presentations

English (EN) (125.4 KB - PDF)

**First published:** 18/02/2021

**Last updated:** 10/07/2023

[View](/en/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-812)

български (BG) (171.95 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/bg/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_bg.pdf)

español (ES) (134.31 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/es/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_es.pdf)

čeština (CS) (137 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/cs/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (90.94 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/da/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (100.6 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/de/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (130.43 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/et/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (180.32 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/el/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_el.pdf)

français (FR) (126.81 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/fr/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (152.18 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/hr/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (131.69 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/is/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_is.pdf)

italiano (IT) (101.72 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/it/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (166.24 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/lv/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (120.11 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/lt/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (156.76 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/hu/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (134.5 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/mt/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (95.84 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/nl/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (97.98 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/no/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_no.pdf)

polski (PL) (141.25 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/pl/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_pl.pdf)

português (PT) (115.13 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/pt/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_pt.pdf)

română (RO) (154.91 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/ro/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (139.56 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sk/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (154.33 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sl/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (140.5 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/fi/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (98.04 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sv/documents/all-authorised-presentations/lenalidomide-krka-dd-epar-all-authorised-presentations_sv.pdf)

Lenalidomide Krka d.d. : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (141.96 KB - PDF)

**First published:** 18/02/2021

**Last updated:** 10/07/2023

[View](/en/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (24)](#file-language-dropdown-896)

български (BG) (271.46 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/bg/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (170.99 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/es/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (237.64 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/cs/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (165.41 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/da/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (167.56 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/de/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (151.86 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/et/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (272.7 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/el/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (164.22 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/fr/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

hrvatski (HR) (201.27 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/hr/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_hr.pdf)

íslenska (IS) (176.31 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/is/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (206.38 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/it/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (221.59 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/lv/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (217.51 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/lt/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (192.63 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/hu/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (242.2 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/mt/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (169.92 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/nl/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (154.48 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/no/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (217.89 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/pl/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (168.82 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/pt/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (281.4 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/ro/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (206.02 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sk/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (191.03 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sl/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (156.36 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/fi/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (164.79 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

10/07/2023

[View](/sv/documents/conditions-member-states/lenalidomide-krka-dd-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Lenalidomide Krka d.d. Active substance lenalidomide hydrochloride hydrate International non-proprietary name (INN) or common name lenalidomide Therapeutic area (MeSH)

- Multiple Myeloma
- Lymphoma, Follicular
- Myelodysplastic Syndromes

Anatomical therapeutic chemical (ATC) code L04AX04

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

**Multiple myeloma**

Lenalidomide Krka d.d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.

Lenalidomide Krka d.d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

Lenalidomide Krka d.d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

**Myelodysplastic syndromes**

Lenalidomide Krka d.d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

**Follicular lymphoma**

Lenalidomide Krka d.d. in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 - 3a).

## Authorisation details

EMA product number EMEA/H/C/005729

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Krka, d.d., Novo mesto

Krka, d.d., Novo mesto

Opinion adopted 10/12/2020 Marketing authorisation issued 11/02/2021 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lenalidomide Krka d.d. : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (198.01 KB - PDF)

**First published:** 26/10/2021

**Last updated:** 10/07/2023

[View](/en/documents/procedural-steps-after/lenalidomide-krka-dd-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Lenalidomide Krka d.d. : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/3809/2021

English (EN) (2.38 MB - PDF)

**First published:** 18/02/2021

**Last updated:** 10/07/2023

[View](/en/documents/assessment-report/lenalidomide-krka-dd-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lenalidomide Krka d.d.

Adopted

Reference Number: EMA/CHMP/651085/2020

English (EN) (211.26 KB - PDF)

**First published:** 11/12/2020

**Last updated:** 10/07/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lenalidomide-krka-dd_en.pdf)

#### News on Lenalidomide Krka d.d.

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

**This page was last updated on** 10/07/2023

## Share this page

[Back to top](#main-content)